Pentraxin 3 levels in bronchoalveolar lavage fluid of lung transplant recipients with invasive aspergillosis
Copyright © 2017 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Invasive aspergillosis is the most common invasive fungal infection in lung transplant recipients. The use of galactomannan testing in bronchoalveolar lavage (BAL) fluid has improved diagnosis of invasive aspergillosis; however, false-positive results can lead to overdiagnosis and unnecessary treatment. The use of proinflammatory markers such as pentraxin 3 (PTX3) may help differentiate between Aspergillus colonization and disease.
METHODS: BAL PTX3 concentrations were measured by enzyme-linked immunosorbent assay in 151 lung transplant recipients and 9 healthy control subjects. Patients were characterized as having Aspergillus colonization or invasive disease according to International Society of Heart and Lung Transplantation criteria. Concomitant PTX3values were compared using Mann-Whitney U and Kruskal-Wallis tests.
RESULTS: We analyzed 322 BAL stored samples and identified 15 invasive aspergillosis events, 38 Aspergillus colonizations, and 17 positive galactomannan with negative Aspergillus cultures. Median BAL PTX3 level was significantly higher in patients with invasive aspergillosis compared with patients with Aspergillus colonization and healthy control subjects (439.20 pg/ml [interquartile range (IQR) 168.18-778.90], 68.93 pg/ml [IQR 13.67-156.74], and 13.67 pg/ml [IQR 13.67-121.18]; p < 0.001). Patients with BAL PTX3 value >319 pg/ml with positive galactomannan and patients with BAL PTX3 value >312 pg/ml with positive Aspergillus culture were 4.5 and 5.5 times more likely to have invasive pulmonary aspergillosis, respectively.
CONCLUSIONS: Our study shows that PTX3 measurements in BAL samples were significantly higher among patients with invasive aspergillosis and may help to identify patients with Aspergillus colonization and false-positive galactomannan in BAL samples.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation - 36(2017), 9 vom: 01. Sept., Seite 973-979 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kabbani, Dima [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
148591-49-5 |
|---|
| Anmerkungen: |
Date Completed 11.06.2018 Date Revised 08.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.healun.2017.04.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM271722681 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM271722681 | ||
| 003 | DE-627 | ||
| 005 | 20231224233329.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.healun.2017.04.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0905.xml |
| 035 | |a (DE-627)NLM271722681 | ||
| 035 | |a (NLM)28487045 | ||
| 035 | |a (PII)S1053-2498(17)31750-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kabbani, Dima |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pentraxin 3 levels in bronchoalveolar lavage fluid of lung transplant recipients with invasive aspergillosis |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.06.2018 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Invasive aspergillosis is the most common invasive fungal infection in lung transplant recipients. The use of galactomannan testing in bronchoalveolar lavage (BAL) fluid has improved diagnosis of invasive aspergillosis; however, false-positive results can lead to overdiagnosis and unnecessary treatment. The use of proinflammatory markers such as pentraxin 3 (PTX3) may help differentiate between Aspergillus colonization and disease | ||
| 520 | |a METHODS: BAL PTX3 concentrations were measured by enzyme-linked immunosorbent assay in 151 lung transplant recipients and 9 healthy control subjects. Patients were characterized as having Aspergillus colonization or invasive disease according to International Society of Heart and Lung Transplantation criteria. Concomitant PTX3values were compared using Mann-Whitney U and Kruskal-Wallis tests | ||
| 520 | |a RESULTS: We analyzed 322 BAL stored samples and identified 15 invasive aspergillosis events, 38 Aspergillus colonizations, and 17 positive galactomannan with negative Aspergillus cultures. Median BAL PTX3 level was significantly higher in patients with invasive aspergillosis compared with patients with Aspergillus colonization and healthy control subjects (439.20 pg/ml [interquartile range (IQR) 168.18-778.90], 68.93 pg/ml [IQR 13.67-156.74], and 13.67 pg/ml [IQR 13.67-121.18]; p < 0.001). Patients with BAL PTX3 value >319 pg/ml with positive galactomannan and patients with BAL PTX3 value >312 pg/ml with positive Aspergillus culture were 4.5 and 5.5 times more likely to have invasive pulmonary aspergillosis, respectively | ||
| 520 | |a CONCLUSIONS: Our study shows that PTX3 measurements in BAL samples were significantly higher among patients with invasive aspergillosis and may help to identify patients with Aspergillus colonization and false-positive galactomannan in BAL samples | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BAL PTX3 | |
| 650 | 4 | |a BAL galactomannan | |
| 650 | 4 | |a inflammatory marker | |
| 650 | 4 | |a invasive aspergillosis | |
| 650 | 4 | |a lung transplantation | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Serum Amyloid P-Component |2 NLM | |
| 650 | 7 | |a PTX3 protein |2 NLM | |
| 650 | 7 | |a 148591-49-5 |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 700 | 1 | |a Bhaskaran, Archana |e verfasserin |4 aut | |
| 700 | 1 | |a Singer, Lianne G |e verfasserin |4 aut | |
| 700 | 1 | |a Bhimji, Alyajahan |e verfasserin |4 aut | |
| 700 | 1 | |a Rotstein, Coleman |e verfasserin |4 aut | |
| 700 | 1 | |a Keshavjee, Shaf |e verfasserin |4 aut | |
| 700 | 1 | |a Liles, W Conrad |e verfasserin |4 aut | |
| 700 | 1 | |a Husain, Shahid |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation |d 1993 |g 36(2017), 9 vom: 01. Sept., Seite 973-979 |w (DE-627)NLM012612367 |x 1557-3117 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2017 |g number:9 |g day:01 |g month:09 |g pages:973-979 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.healun.2017.04.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2017 |e 9 |b 01 |c 09 |h 973-979 | ||